|
English
|
正體中文
|
简体中文
|
2817185
|
|
???header.visitor??? :
27700732
???header.onlineuser??? :
446
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"laskin j"???jsp.browse.items-by-author.description???
Showing items 1-5 of 5 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 國立成功大學 |
2020 |
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
|
Papadimitrakopoulou, V.A.;Mok, T.S.;Han, J.-Y.;Ahn, M.-J.;Delmonte, A.;Ramalingam, S.S.;Kim, S.W.;Shepherd, F.A.;Laskin, J.;He, Y.;Akamatsu, H.;Theelen, W.S.M.E.;Su, W.-C.;John, T.;Sebastian, M.;Mann, H.;Miranda, Miranda M.;Laus, G.;Rukazenkov, Y.;Wu, Y.-L. |
| 國立東華大學 |
2008 |
Preparation of novel catalysts using soft landing of mass-selected ions on surfaces
|
Laskin, J.; P. Wang, Z. Yang; O. Hadjar; W.-P. Peng; R. G. Cooks |
Showing items 1-5 of 5 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
